Summary by Futu AI
SCICLONE PHARMA (SCICLONE PHARMA) ANNOUNCED ON 30 APRIL 2024 THAT ITS EXECUTIVE OFFICER LIN HUI-BIN HAD ENTERED INTO A SHARE TRANSACTION BY AGREEMENT ON 29 APRIL 2024 PURSUANT TO RULE 22 OF THE HONG KONG CODE OF BUSINESS ACQUISITIONS AND MERGERS. Lin Huibin received a 10,000 share bonus under the Initial Public Offering Limited Share Unit Scheme and purchased the lot at HK$0.0000 per share. The number of holdings after the transaction increased to 29,967 shares, representing 0.0048% of the issued shares of the company.